Related Experiment Videos

New targets for the treatment of vascular diseases and diabetes

J V Schloss1

  • 1Department of Medicinal Chemistry, University of Kansas, 4070 Malott Hall, Lawrence, KS 66045, USA. schloss@kuhub.cc.ukanss.edu

Idrugs : the Investigational Drugs Journal
|May 10, 2008
PubMed

Insights

This symposium explored peroxisome proliferator-activated receptors (PPARs), focusing on how thiazolidinediones alter lipid metabolism and how benzothiepines/benzothiazepines reduce cholesterol by inhibiting bile acid transport.

Area of Science:

  • Biochemistry
  • Endocrinology
  • Pharmacology

Background:

  • Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors crucial for glucose and lipid homeostasis.
  • PPARs interact with retinoic acid receptors (RXRs) and are activated by unsaturated fatty acids.
  • This symposium focused on novel chemical classes targeting PPARs and related pathways.

Purpose of the Study:

  • To discuss advancements in understanding PPARs and their role in metabolic regulation.
  • To present novel chemical entities affecting lipid metabolism and cholesterol levels.
  • To explore therapeutic strategies involving PPAR modulation and bile acid transport inhibition.

Main Methods:

  • Discussion of thiazolidinediones as direct PPAR agonists.
  • Presentation of benzothiepines/benzothiazepines as inhibitors of the ileal bile acid transporter (IBAT).
  • Focus on the interplay between nuclear receptors and metabolic pathways.

Main Results:

  • Thiazolidinediones were shown to directly interact with PPARs, altering lipid metabolism.
  • Benzothiepines/benzothiazepines were identified as inhibitors of IBAT, leading to reduced cholesterol.
  • Increased bile acid excretion was observed as a mechanism for cholesterol reduction.

Conclusions:

  • Novel chemical scaffolds offer distinct mechanisms for metabolic control.
  • Targeting PPARs and IBAT presents promising therapeutic avenues for metabolic disorders.
  • Understanding these pathways is key to developing treatments for dyslipidemia and related conditions.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...